The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy.

Abstract

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study provided extensive data on predisposing factors, consequences, and prevention of atrial fibrillation (AF) in patients with hypertension and left ventricular (LV) hypertrophy. Randomized losartan-based treatment was superior to atenolol-based treatment for reducing new-onset AF and complications, especially stroke, associated with new-onset or pre-existing AF. Potential mechanisms of AF prevention by angiotensin receptor blockade supported by LIFE results include greater reduction in left atrial size and LV hypertrophy. Differential effects of antihypertensive treatment on the left atrium and left ventricle may help prevent AF and reduce risk of stroke associated with hypertensive heart disease.

• Authors: Kristian Wachtell, Richard B Devereux, Paulette A Lyle, Peter M Okin, Eva Gerdts
• Journal: Therapeutic advances in cardiovascular disease (Ther Adv Cardiovasc Dis) Vol. 2 Issue 6 Pg. 507-13 (Dec 2008) ISSN: 1753-9447 [Print] England
• PMID: 19124445 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Angiotensin II Type 1 Receptor Blockers

Topics

• Angiotensin II Type 1 Receptor Blockers (therapeutic use)
• Atrial Fibrillation (epidemiology, prevention & control)
• Heart Atria (physiopathology)
• Humans
• Hypertrophy, Left Ventricular (drug therapy, epidemiology)
• Randomized Controlled Trials as Topic
• Risk Factors
• Risk Reduction Behavior
• Stroke (epidemiology, prevention & control)